Physician profile
Lauren E Teter
NPI 1710236112
$4,952.17
in general payments reported to CMS, 2019-2025
23 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $795 · 2023: $1,207 · 2024: $1,330 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.55 |
| Education | $475.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,272.99 | 2021-2025 | Tremfya |
| Abbvie INC. | $482.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $362.49 | 2021-2025 | |
| Dermavant Sciences, INC. | $313.71 | 2023-2024 | Vtama |
| Incyte Corporation | $250.10 | 2022-2025 | Opzelura |
| Ucb, INC. | $241.95 | 2022-2025 | Bimzelx, Briviact |
| Lilly USA, LLC | $239.73 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $233.38 | 2023-2024 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $229.85 | 2022-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $192.83 | 2021-2025 | Aklief |
| Leo Pharma INC. | $181.20 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Genzyme Corporation | $168.70 | 2025 | |
| Arcutis Biotherapeutics, INC. | $144.03 | 2023-2025 | Zoryve |
| Organon LLC | $105.67 | 2025 | Vtama, Hadlima |
| Amgen INC. | $95.58 | 2023-2025 | Otezla, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $90.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $86.51 | 2022-2024 | Sotyktu |
| Pfizer INC. | $83.40 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.92 | 2022-2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.30 | 2025 | Cabtreo, Jublia |
| Almirall LLC | $22.09 | 2023 | Seysara |
| Biofrontera INC. | $18.24 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $16.64 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Teter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.